Sermorelin: Evidence, Legal Status, and Safety
Sermorelin is a growth-hormone-releasing hormone (GHRH) analog that was FDA-approved decades ago, under the brand Geref, for a narrow pediatric diagnostic and growth-hormone-deficiency use; that branded product was discontinued, and today it's used almost entirely through compounding pharmacies for a much broader wellness pitch (anti-aging, sleep, body composition) that its old approval never covered. Andrew Huberman has disclosed personal, off-and-on use and notes it can reduce REM sleep.
Understand the mechanism and its history A GHRH analog, shorter-acting than CJC-1295, historically the longest-marketed GH-secretagogue peptide; it was FDA-approved decades ago under the brand Geref for a narrow pediatric diagnostic and deficiency use before that product was discontinued.
The historical FDA approval is real, but it covers a different use than what sermorelin is sold for today.
See what current-use evidence actually exists For today's popular use, anti-aging, recovery, sleep, body composition in healthy adults, there is essentially no controlled human evidence. The historical Geref approval was for pediatric growth-hormone-deficiency diagnosis and treatment, not this use.
An old, discontinued approval for a completely different population and purpose should not be read as evidence for today's wellness marketing.
Know what needs independent confirmation Multiple industry sources describe sermorelin as currently available through compounding pharmacies with a prescription, more permissive than the reported Category 2 restriction on CJC-1295 and ipamorelin. This has not been independently confirmed against the FDA's current 503A bulk-substance list, so treat it as unverified rather than settled.
This is exactly the kind of claim that should not harden into fact through repetition before it's independently checked.
Know the class-effect caveats and a real disclosure Same GH-axis class-effect caveats as other secretagogues apply. Because it is more often obtained through a compounding pharmacy with a prescription than the outright “research chemical” gray market, purity risk is somewhat lower than BPC-157, TB-500, or MK-677, but it is still not FDA-reviewed for the wellness indications it is marketed for. Andrew Huberman has disclosed personal use and notes it can reduce REM sleep.
A named expert's personal disclosure is one data point, not controlled evidence, but it is a genuine, first-person account worth including honestly.
Sermorelin was actually FDA-approved decades ago under the brand Geref, for diagnostic use and pediatric growth-hormone-deficiency treatment.
View sources
Huberman Lab: Benefits & Risks of Peptide Therapeutics for Physical & Mental Health (sermorelin segment, personal disclosure)
Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Editorial disclosure. This protocol is written and fact-checked by the YourProtocol editorial team directly from the primary sources cited below; it is not written or reviewed by any outside expert.
Is this for you
- Anyone considering sermorelin who wants the honest evidence before discussing it with a clinician
- Readers who assumed sermorelin's old FDA approval covers its current wellness marketing
- Readers comparing sermorelin's legal status to CJC-1295 or ipamorelin
- Readers who want to know what a named expert's personal experience with sermorelin actually was
Cautions
- The FDA approval for sermorelin (Geref) was for a narrow pediatric diagnostic and deficiency use; that product is discontinued and the approval does not cover today's wellness marketing.
- Its current compounding-legal status is reported by industry sources but not independently confirmed against FDA's current bulk-substance list; treat as unverified.
- Not FDA-reviewed for anti-aging, recovery, sleep, or body-composition use in healthy adults.
- Educational only, not medical advice.